Mengke Niu
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 16
- Cancer Cells and Metastasis 6
- CAR-T cell therapy research 4
- Pancreatic and Hepatic Oncology Research 3
- Immunology top 2%
- Immunotherapy and Immune Responses 8
- Immune Cell Function and Interaction 6
- Immune cells in cancer 4
- Cancer Research top 5%
- Biotechnology top 5%
- Cancer Research and Treatments 4
- Cited by
- OncologyImmunologyCancer Research
- Journals
- International Journal of Hydrogen Energy (1 paper)Frontiers in Immunology (5 papers)Molecular Cancer (3 papers)
- Partner nations
- ChinaSwedenUnited States
In The Last Decade
Mengke Niu
32 papers receiving 3.3k citations
Hit Papers
Peers
Comparison fields: 5 of 111
- Oncology 1.8k
- Immunology 1.4k
- Cancer Research 421
- Biotechnology 134
- Pulmonary and Respiratory Medicine 494
Countries citing papers authored by Mengke Niu
This map shows the geographic impact of Mengke Niu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengke Niu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengke Niu more than expected).
Fields of papers citing papers by Mengke Niu
This network shows the impact of papers produced by Mengke Niu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengke Niu. The network helps show where Mengke Niu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mengke Niu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 9 | |
| 3 | 2024 | 13 | |
| 4 | 2024 | 29 | |
| 5 | 2024 | 17 | |
| 6 | 2024 | 5 | |
| 7 | 2024 | 15 | |
| 8 | 2023 | 7 | |
| 9 | 2023 | 61 | |
| 10 | 2023 | 27 | |
| 11 | Exploiting innate immunity for cancer immunotherapybreakdown → | 2023 | 113 |
| 12 | 2022 | 95 | |
| 13 | 2022 | 12 | |
| 14 | Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsbreakdown → | 2022 | 901 |
| 15 | 2021 | 108 | |
| 16 | 2021 | 162 | |
| 17 | 2021 | 5 | |
| 18 | CD44 as a tumor biomarker and therapeutic targetbreakdown → | 2020 | 266 |
| 19 | 2019 | 1 | |
| 20 | 2019 | 0 |
About Mengke Niu
Mengke Niu is a scholar working on Oncology, Immunology and Biotechnology, having authored 34 papers that have together received 3.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (16 papers), Immunotherapy and Immune Responses (8 papers), Immune Cell Function and Interaction (6 papers), Cancer Cells and Metastasis (6 papers), Cancer Research and Treatments (4 papers), CAR-T cell therapy research (4 papers), Immune cells in cancer (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). The work is most often cited by research in Oncology (1.8k citations), Immunology (1.4k citations) and Cancer Research (421 citations). Mengke Niu has collaborated with scholars based in China, Sweden and United States. Frequent co-authors include Kongming Wu, Ming Yi, Shuangli Zhu, Xiaoli Zheng, Hong Ge, Suxia Luo, Yuze Wu, Linping Xu, Tianye Li and Qi Mei. Their work appears in journals such as International Journal of Hydrogen Energy, Frontiers in Immunology and Molecular Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.